Literature DB >> 33748033

Liver Imaging and Data System (LI-RADS) Version 2018 and Other Imaging Features in Intrahepatic Cholangiocarcinoma in Chinese Adults with vs. without Chronic Hepatitis B Viral Infection.

Ying-Ying Liang1,2, Shuo Shao3,4, Sichi Kuang1, Jingbiao Chen1, Jing Zhou1, Bingjun He1, Linqi Zhang1, Yao Zhang1, Kathryn J Fowler5, Jin Wang1.   

Abstract

Purpose: To describe liver imaging reporting and data system (LI-RADS) version 2018 and other MRI imaging features in intrahepatic mass-forming cholangiocarcinoma (iCCA) in Chinese adults with vs. without chronic hepatitis B viral (HBV) infection.
Methods: We retrospectively enrolled 89 patients with pathologically proven iCCA after multiphase imaging performed between 2004 and 2017 at a tertiary medical center in southern China. Based on whether patients had chronic HBV, iCCA was divided into two subgroups: HBV-positive (n = 50 patients, including 9 with cirrhosis) vs. HBV-negative (n = 39 patients, including 14 with hepatolithiasis and 25 with no identifiable risk factor for iCCA; none had cirrhosis). Two independent abdominal radiologists in consensus reviewed the largest mass in each patient to assign LI-RADS v2018 features; they also scored each observation's shape and location. Imaging features were compared using chi-square or Fisher's exact tests.
Results: Most iCCAs in HBV-positive (88% (44/50)) and HBV-negative (97% (38/39)) patients had at least one LR-M feature. Compared to iCCAs in HBV-negative patients, iCCAs in HBV-positive patients were more likely to have at least one major feature of HCC (46% (23/50) vs. 8% (3/39), P < 0.001) and more likely to be smooth (42% (21/50) vs. 10% (4/39), P = 0.001). Six of 50 (12%) iCCAs in HBV-positive patients and 1/39 (3%) iCCAs in HBV-negative patients had at least one major feature of HCC without any LR-M feature. Conclusions: In this retrospective single-center study in Chinese adults, iCCAs in HBV-positive patients were more likely to resemble HCCs than iCCAs in HBV-negative patients.
Copyright © 2021 Ying-ying Liang et al.

Entities:  

Year:  2021        PMID: 33748033      PMCID: PMC7952186          DOI: 10.1155/2021/6639600

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  42 in total

1.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

2.  American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: a pictorial essay.

Authors:  Fabio Piscaglia; Stephanie R Wilson; Andrej Lyshchik; David Cosgrove; Christoph F Dietrich; Hyun-Jung Jang; Tae Kyoung Kim; Veronica Salvatore; Juergen Karl Willmann; Claude B Sirlin; Yuko Kono
Journal:  Ultraschall Med       Date:  2017-03-22       Impact factor: 6.548

3.  Differentiation of Intrahepatic Cholangiocellular Carcinoma from Hepatocellular Carcinoma in the Cirrhotic Liver Using Contrast-enhanced MR Imaging.

Authors:  Georg J Wengert; Pascal A T Baltzer; Hubert Bickel; Patrick Thurner; Julia Breitenseher; Mathias Lazar; Matthias Pones; Markus Peck-Radosavljevic; Florian Hucke; Ahmed Ba-Ssalamah
Journal:  Acad Radiol       Date:  2017-07-26       Impact factor: 3.173

Review 4.  2017 Version of LI-RADS for CT and MR Imaging: An Update.

Authors:  Khaled M Elsayes; Jonathan C Hooker; Michelle M Agrons; Ania Z Kielar; An Tang; Kathryn J Fowler; Victoria Chernyak; Mustafa R Bashir; Yuko Kono; Richard K Do; Donald G Mitchell; Aya Kamaya; Elizabeth M Hecht; Claude B Sirlin
Journal:  Radiographics       Date:  2017 Nov-Dec       Impact factor: 5.333

5.  Prognostic impact of hepatitis B virus infection in patients with intrahepatic cholangiocarcinoma.

Authors:  Chul-Soo Ahn; Shin Hwang; Young-Joo Lee; Ki-Hun Kim; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Sung-Gyu Lee
Journal:  ANZ J Surg       Date:  2016-09-06       Impact factor: 1.872

Review 6.  Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma.

Authors:  Nestor F Esnaola; Joshua E Meyer; Andreas Karachristos; Jennifer L Maranki; E Ramsay Camp; Crystal S Denlinger
Journal:  Cancer       Date:  2016-01-22       Impact factor: 6.860

7.  The value of Gd-BOPTA- enhanced MRIs and DWI in the diagnosis of intrahepatic mass-forming cholangiocarcinoma.

Authors:  C C Xu; Y F Tang; X Z Ruan; Q L Huang; L Sun; J Li
Journal:  Neoplasma       Date:  2017       Impact factor: 2.575

Review 8.  Risk factors for cholangiocarcinoma.

Authors:  Tamir Ben-Menachem
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-08       Impact factor: 2.566

9.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update.

Authors:  Shahid A Khan; Brian R Davidson; Robert D Goldin; Nigel Heaton; John Karani; Stephen P Pereira; William M C Rosenberg; Paul Tait; Simon D Taylor-Robinson; Andrew V Thillainayagam; Howard C Thomas; Harpreet Wasan
Journal:  Gut       Date:  2012-08-15       Impact factor: 23.059

10.  Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors.

Authors:  Rui-Qing Liu; Shu-Jing Shen; Xiu-Feng Hu; Jie Liu; Li-Juan Chen; Xing-Ya Li
Journal:  Cancer Cell Int       Date:  2013-10-18       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.